About

Leadership

Steve Potts

Steve Potts, PhD, MBA

Cofounder, CEO & Director
 

Steve Potts, PhD, MBA (Cofounder & CEO) leads OncoMyx. Steve has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He has a proven track record of success, with his last three companies all with significant shareholder returns. He was Vice President of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of the testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule was the first in industry to receive breakthrough designation equivalents in the USA, Europe, and Japan. Prior to Ignyta, he bootstrapped his first company as founding CEO, Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M. He also built the Bioinformatics Department for a Fortune 500 Company, Quest Diagnostics, which subsequently delivered $1B of annual revenue. He earned a BS in Physics from Wheaton College, Illinois and PhD in Biological Engineering and MBA from the University of California Davis.

Close
Leslie Sharp

Leslie Sharp, PhD

Chief Scientific Officer
 

Leslie Sharp, PhD (CSO) leads scientific activities and development of IND candidates. Trained as an immunologist, Leslie joined the immuno-oncology team at Pfizer, where she spent five years in progressively expanding areas of responsibility in the design and development of IO biologics. She has worked on multiple discovery oncology drug programs in pharmaceutical and biotech settings including GNF (Novartis), BioAtla, and CYBIOS. She is an accomplished scientific and strategic leader with extensive experience in drug discovery and development. She has a strong track record of building high performing teams and delivering results and is a highly motivated leader capable of effectively working in dynamic multi-disciplinary teams. She earned a BS from University of Utah and PhD in Biology from University of California, San Diego.

Close
jamie-doran

Jamie Doran, MSc, DABT, ERT

Vice President of Operations
 

Jamie Doran, M.Sc., DABT, ERT, leads cross-functional program management and operations at OncoMyx. Jamie has nearly 20 years experience in the biotech and pharmaceutical industry, with progress responsibility and proven track-record of successful cross-functional leadership and management of global product registrations. She has managed more than a hundred projects and has been responsible for cross-functional team management and monitoring of multi-million-dollar budgets and multi-year programs. Jamie has a unique background in preclinical program management and very strong scientific expertise that she gained in her roles in the biotechnology industry as well as in consulting to clients in pharmaceutical, biotech, and medical device industries. She has been accountable for the full scope of drug development programs (including regulatory strategy, R&D, and clinical testing) for small molecules and advanced therapeutics and is thus thoroughly versed in all aspects of lifecycle management for pharmaceutics and products of biotechnology. As a consultant to the industry for several years, Jamie provided expert advice in drug development, including strategic advice, gap analyses, program planning, and program management for novel compounds as well as second-generation products. She has extensive experience with designing, implementing, and critically evaluating IND-enabling programs as well as review and preparation of regulatory packages for new drug and biologic submissions. Her most recent tenure was a founding member of the Executive team (VP, Drug Development) at Appili Therapeutics Inc. (XTSE: APLI), a development company focused on treatment and prevention of infectious disease. Jamie holds a Bachelor’s of Science from University of Western Ontario in Pharmacology and Toxicology and a Master’s of Science from Purdue University in Medicinal Chemistry and Molecular Pharmacology. Ms. Doran is a Diplomat of the American Board of Toxicology and is a European Registered Toxicologist with the Institute of Biology & British Toxicology Society (London, United Kingdom).

Close
danya-norton

Danya Norton

Vice President of People
 

Danya Norton leads the People & Culture function for OncoMyx. Danya has spent her career working in the field organization effectiveness to unleash the potential of individuals and drug discovery teams. She has more than 17 years of experience of partnering with drug discovery teams in both the global pharmaceutical and biotech startup environments to drive innovative cultures where science and strategy thrive. Prior to joining OncoMyx, Danya was a co-founder of Agate Partners where she partnered with early biotech start-ups to define and align their strategy, culture and leadership development programs.  She held the role of Vice President of People & Culture at Human Longevity as well as at the Novartis Institute for BioMedical Research (NIBR), and Novartis Institute for Functional Genomics (GNF).

Close

Advisors

James Burke

James Burke, MD

Medical Advisor
 

James Burke, MD (Medical Advisor) advises the company on clinical development. James has advised Turnstone Biologics, served as Chief Medical Officer at Sillajen Biotherapeutics and Vice President of Clinical Research at Jennerex. James oversaw global clinical development for Sillajen including design and oversight of clinical trials of gene and immunotherapy agents for hepatocellular carcinoma (now in Phase 3), renal cell carcinoma, colorectal cancer, and various other solid tumors. James has over 15 years of preclinical and clinical experience in the field of gene and immunotherapy including work with various oncolytic virus platforms, tumor vaccines, and other gene therapy related agents. Prior to SillaJen and Jennerex, he was Associate Director of Clinical Research at Cell Genesys and Director of Clinical Research at a regional cancer center. James earned a BS in Biochemistry from University of California, San Diego and MD from Georgetown University. He completed a general internal medicine residency at University of California, San Diego followed by a Hematology-Oncology Fellowship at University of California, San Francisco. James is Board Certified in both Hematology and Oncology.

Close
George Roth

Georg Roth, PhD

CMC Advisor
 

Georg Roth, PhD (CMC Advisor) advises the company on manufacturing. Georg served as Chief Operating Officer and Senior Vice President of Technical Operations at SillaJen Biotherapeutics, where he was responsible for managing U.S. operations and heading all technical functions for the development of oncolytic viruses. Prior to SillaJen, he worked as Vice President of Technical Operations at Jennerex, with responsibilities in process development, analytical development, and manufacturing of oncolytic viruses. Georg was Director of Technical Affairs at Dynavax and also established an international consulting company specializing in bioprocess technology. He also held positions of increasing responsibility at Berlex Laboratories. Altogether Georg has over 30 years of experience in the pharmaceutical industry. Georg earned a diploma and PhD in Chemical Engineering from Technical University Berlin, Germany.

Close
Matt Fust

Matt Fust, MBA

Finance Advisor
 

Matt Fust, MBA (Finance Advisor) advises the company on financial matters. He is currently a board member and advisor to life sciences companies. Matt retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, where he served through its acquisition by Amgen. Matt served as Chief Financial Officer at Jazz Pharmaceuticals and Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation. Matt serves on the board of directors of the following publicly traded companies: Crinetics, Dermira, Atara, MacroGenics, and Ultragenyx. Matt previously served on the board of directors at Sunesis Pharmaceuticals. Matt earned a BA from University of Minnesota and MBA from Stanford University.

Close
John Wallen

John Wallen, JD, PhD

Intellectual Property Advisor
 

John Wallen, JD, PhD (Intellectual Property Advisor) advises the company on intellectual property matters. John specializes in creating and helping to execute the IP strategy for emerging biotech companies. He is currently VP of Intellectual Property at Avidity Biosciences and an advisor at Crinetics Pharmaceuticals and Vividion Therapeutics. Previously, he held the position of Vice President, Intellectual Property & Corporate Legal at Ambrx. John was a partner in the Technology/Intellectual Property, Life Sciences, and Patent Litigation groups of the law firm Preston Gates & Ellis LLP in San Diego. John served as a patent attorney in the law department of Johnson & Johnson. He worked for Merck, serving first as a scientist and then as a patent agent. John is a patent attorney registered with the US Patent and Trademark Office. John earned a BS in Biology from State University of New York College at Oswego, MS in Clinical Microbiology from Long Island University, JD from Seton Hall Law School, and PhD in Molecular Biology from University of Pennsylvania.

Close

Founders

Grant McFadden

Grant McFadden, PhD

Cofounder, Research Advisor, & Director
 

Grant McFadden, PhD is founder, research advisor, and director at OncoMyx. He is one of the top global leaders in oncolytic viruses with a specialization in poxviruses, including myxoma. The McFadden lab pioneered the field of viral immune subversion (also called “anti-immunology”) and is credited with the discovery of a wide spectrum of virus-derived inhibitors of the immune system.

Close
Steve Potts

Steve Potts, PhD, MBA

Cofounder, CEO & Director
 

Steve Potts, PhD, MBA (Cofounder & CEO) leads OncoMyx. Steve has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He has a proven track record of success, with his last three companies all with significant shareholder returns. He was Vice President of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of the testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule was the first in industry to receive breakthrough designation equivalents in the USA, Europe, and Japan. Prior to Ignyta, he bootstrapped his first company as founding CEO, Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M. He also built the Bioinformatics Department for a Fortune 500 Company, Quest Diagnostics, which subsequently delivered $1B of annual revenue. He earned a BS in Physics from Wheaton College, Illinois and PhD in Biological Engineering and MBA from the University of California Davis.

Close
Michael Wood

Michael Wood, MBA

Cofounder
 

Michael Wood, MBA, has more than two decades of experience that spans being trained at three Fortune 100 companies through founding multiple biotech companies, including OncoMyx, and reporting directly to the CEO and interacting with Boards of Directors at various companies over the past decade. His core areas of expertise are fundraising, business development & commercial. From a fund-raising perspective, he has helped orchestrate startup series A financings through IPOs and follow-ons as an investment banker at Morgan Stanley. His business development accomplishments span a variety of buy-side transactions at Abbott/Abbvie and sell-side transactions at both private and publicly-traded biotechs including a billion-dollar biotech-big pharma partnership with Takeda. And from a commercial perspective, he has helped launch multiple blockbuster products both in the field and in-house, as well as lead a biotech market research department through a commercial launch. Most recently, he was Vice President of Corporate Development & Operations at Crinetics Pharmaceuticals (NASDAQ: CRNX), where he joined ex-Neurocrine Biosciences drug hunters to venture fund and operate the company on its way to the clinic and an IPO. He earned a BS in Molecular & Cell Biology, summa cum laude and phi beta kappa, from UC Berkeley, where his boat won the rowing national championship and set a world record, and MBA in Finance & Strategy from the University of Chicago.

Close